The Sobering Reality of Stopping Treatment
A large-scale study published in The Lancet Regional Health Europe in early November 2026 delivered a stark warning for people with Type 2 diabetes who stop using GLP-1 medications. The research, which analyzed health records from over 80,000 patients
in Italy, found that discontinuing the drugs was associated with approximately double the risk of a major cardiovascular event—such as a non-fatal heart attack or stroke—or death from any cause. During the study period, a staggering 60.5% of patients had stopped their GLP-1 therapy. The findings underscore what many doctors have been saying: these medications are a long-term treatment for a chronic condition, not a short-term fix. When the medication is removed, its protective benefits appear to fade as well.
Why Do So Many People Stop?
The reasons for stopping GLP-1 drugs are numerous and complex. Many patients discontinue treatment due to significant gastrointestinal side effects like nausea, vomiting, and diarrhea. For others, the high cost and inconsistent insurance coverage make long-term use unsustainable. Previous studies have shown that anywhere from 20% to over 50% of users stop within the first year. Sometimes, shortages can interrupt access, while other patients may simply wish to stop after reaching their weight or health goals, believing the work is done. However, as the new research indicates, the biological effects of the drugs are tied to their continued use, and stopping can set the stage for a rapid reversal of the progress made.
Beyond the Cardiovascular Risks
While the Italian study focused on cardiovascular events and mortality in diabetes patients, other recent research presented at ObesityWeek 2026 sheds light on the well-known issue of weight regain. One study following over 45,000 patients found that, on average, people regained about 70% of the weight they lost after stopping semaglutide or tirzepatide. Half of the lost weight was typically regained within five to six months. This happens because the drugs work by suppressing appetite and quieting 'food noise'; when they are stopped, hunger and cravings often return with intensity. Beyond weight, other metabolic markers like blood sugar, blood pressure, and cholesterol levels that improve during treatment can also revert toward their previous levels after discontinuation.
Is It Rebound or a Return to Baseline?
Experts urge caution in interpreting the findings, noting that these observational studies show a strong association, not necessarily direct causation. It’s possible that those who stop treatment are already at a higher underlying risk, or cease the medication due to another illness that itself raises their risk. As one cardiologist noted, it's less about stopping the drug causing a heart attack and more about continuing the drug preventing one. The benefits are active only while you take the medication. When treatment ends, the body's risk factors for heart disease and weight gain are no longer being actively managed by the drug, leading to a return to a higher-risk state. The data from a Cleveland Clinic study further supports this, showing that patients who stopped GLP-1s with no further treatment had the smallest weight loss and the least improvement in blood pressure and blood sugar over two years.
What This Means For Your Health
The consistent message from this wave of new research is clear: GLP-1s are powerful tools for managing the chronic diseases of obesity and Type 2 diabetes, but they are not a cure. The decision to stop taking them should not be made lightly or without a clear plan. For patients who must discontinue due to side effects, cost, or other reasons, it is crucial to discuss alternative strategies with a healthcare provider. Options may include switching to a different medication or, for some, considering bariatric surgery, which studies show leads to the most sustained weight loss. Ultimately, the findings reinforce that managing these conditions requires a lifelong commitment, whether through medication, intensive lifestyle changes, or other medical interventions.
















